An alternative approach to potentiate APN inhibitory activity and overcome resistance in malignancies involves combination therapy, such as co-administration of tosedostat with statins—including simvastatin, fluvastatin, lovastatin, and pravastatin—for the treatment of aminopeptidase-resistant acute myeloid leukemia (AML).130 The therapeutic efficacy of APN inhibitors in cancer treatment can be enhanced through synergy with other anticancer agents, such as paclitaxel. The gene discussed is ANPEP; the disease is cancer.